Neogenomics Inc. (NEO)

Precedente Chiudi:

$13.85

Aprire:

$13.91

Volume 24 ore:

798.44K

Capitalizzazione di mercato:

$1.81B

Reddito:

$591.64M

Utile/perdita netta:

$-87.97M

Rapporto P/E:

-18.36

EPS:

-0.77

Flusso di cassa netto:

$-30.71M

1 W Prestazione:

+4.51%

1M Prestazione:

-6.73%

6M Prestazione:

-2.55%

1 anno Prestazione:

-1.81%

Intervallo 1D:

$13.68

$14.35

Portata 52W:

$11.03

$21.22

Neogenomics Inc. Stock (NEO) Company Profile

Nome

Neogenomics Inc.

Settore

Healthcare (1191)

Industria

Diagnostics & Research (66)

Telefono

239-768-0600

Indirizzo

12701 Commonwealth Drive, Suite 9, Fort Myers, FL

Dipendente

1,000

Cinguettio

@NeoGenomics

Prossima data di guadagno

2024-05-23

Ultimi documenti SEC

NEO's Discussions on Twitter

Neogenomics Inc. Stock (NEO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-29	Reiterato	BTIG Research	Buy
2023-08-21	Aggiornamento	Stephens	Equal-Weight → Overweight
2023-05-16	Downgrade	Raymond James	Outperform → Mkt Perform
2023-05-09	Aggiornamento	BTIG Research	Neutral → Buy
2023-02-24	Aggiornamento	The Benchmark Company	Hold → Buy
2023-02-01	Aggiornamento	Needham	Hold → Buy
2022-08-26	Downgrade	The Benchmark Company	Buy → Hold
2022-08-22	Downgrade	Needham	Buy → Hold
2022-06-03	Iniziato	Piper Sandler	Overweight
2022-03-29	Downgrade	BofA Securities	Buy → Neutral
2022-03-29	Downgrade	Stephens	Overweight → Equal-Weight
2022-01-18	Ripresa	Stephens	Overweight
2021-12-16	Iniziato	Cowen	Outperform
2021-11-05	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-03	Iniziato	Goldman	Buy
2021-02-25	Ripresa	Needham	Buy
2021-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
2021-01-28	Iniziato	Truist	Buy
2020-12-11	Ripresa	BTIG Research	Buy
2020-10-28	Reiterato	Needham	Buy
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-08-28	Iniziato	Guggenheim	Buy
2020-07-29	Reiterato	Needham	Buy
2020-06-25	Iniziato	BofA/Merrill	Buy
2020-04-21	Ripresa	Stephens	Overweight
2020-03-02	Ripresa	Craig Hallum	Buy
2020-02-28	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Downgrade	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Reiterato	Needham	Buy
2019-05-01	Reiterato	Needham	Buy
2019-03-29	Reiterato	Needham	Buy
2019-01-03	Iniziato	Needham	Buy
2018-10-24	Aggiornamento	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Iniziato	Leerink Partners	Outperform
2018-05-02	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Downgrade	BTIG Research	Buy → Neutral
2017-08-24	Iniziato	Gabelli & Co	Buy
2016-12-15	Iniziato	Cantor Fitzgerald	Overweight

Mostra tutto

Neogenomics Inc. Borsa (NEO) Ultime notizie

Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Zacks Investment Research

Wall Street Breakfast: The Week Ahead

Seeking Alpha

All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy

Zacks Investment Research

Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?

Zacks Investment Research

Neogenomics Inc. Azioni (NEO) Dati Finanziari

Neogenomics Inc. (NEO) Reddito 2024

Neogenomics Inc. (NEO) Reddito netto 2024

Neogenomics Inc. (NEO) Flusso di cassa 2024

Neogenomics Inc. (NEO) Utile per azione 2024